Tried to do my part over there with the following
Tried to do my part over there with the following post:
The less IPIX gains today the more it proves that IPIX has the big boys scared to death.
Does anyone believe news of this positive caliber from a small startup would cause such a runup in volume but no price gain if it was just a bit player? Of course not.
Our lack of share price appreciation shows IMO that either a BP, or BPs, a possible hedge fund or multiple hedge funds, day trader groups, etc are worried ****less over IPIX succeeding and throwing their aims in the dumpster.
Does it really matter what today's ending price is other than a feel good?
Who other than the core group that has been following IPIX for months to years saw this PR? IMO, very few.
So why the volume? Could just be trading groups such as Cl** Trader doing their pump and dump price action. We know it certainly isn't any longs selling.
IPX with Brilacidin and Kevetrin could upset the largest horse cart in America (as shown by the amount paid by lobbyists to further their cause)- that of the Big Pharmas. Brilacidin alone may undo the cash cow revenues of MANY currently large drugs these BPs rely on for their income.
Until we see the government/major media extol the greatness of Brilacidin, until the peer review article is published and we get extremely positive feedback from top medical doctors/scientists, and until we get some large funds thru whatever means our share price remains in the hands of those wanting it to remain low.
About time posters quit asking every day about the share price, whining that it isn't going up like they want, questioning if things really are going on behind the scenes (I actually take many of these folks to be snakes in the grass or just plain stupid newbies).
We have the golden egg layer in Brilacidin IMO and not far behind is Kevetrin which just needs to get into pill form to start strutting its stuff.
There is a season..... goes a popular song. Our season has started and the rewards are quickly coming as well (most likely prior to the end of the year) so lets settle down and bask in the PRs good news instead of wailing about the stock price.
I bought another nice chunk (at least for me) today as each PR lowers the risk IMO and currently it is just about as hard to find as is CV19 after being hit with a shot of Brilacidin.
It was removed within minutes by jackhole SS so I have requested a review. If this post isn't on topic, what is?
15
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...
Continue Reading
Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...
Continue Reading
A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...
Continue Reading
July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...
Continue Reading
Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...
Continue Reading
A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...
Continue Reading
Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...
Continue Reading
Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...
Continue Reading
A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....
Continue Reading
A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...
Continue Reading
Top 5 Most Recently Viewed Articles
You know, every now and then, a glimmer of potential bites back against the usual cancer battle headlines. Today, Curis, Inc. (NASDAQ: CRIS) is that flickering hope in the often murky world of biotech, making moves to stir things up with its TakeAim CLL study. Let's do a deep dive into exactly what this could mean for the world battling chronic lymphocytic leukemia....
Continue Reading
Antimicrobial Coating Market Predicted to Surge The Global antimicrobial coating market is on track for remarkable growth, projected to reach US$ 8.82 billion by 2031 from US$ 3.78 billion in 2023. This substantial growth corresponds to a compound annual growth rate (CAGR) of 11.2% throughout the forecast period. Growing Demand for Antimicrobial Coatings One of the...
Continue Reading
Recent Transactions by Management at Royal Unibrew A/S Royal Unibrew A/S, a prominent player in the beverage industry, has recently made important disclosures regarding share transactions executed by its key management personnel. This announcement is made in accordance with the regulations aimed at promoting transparency in the market. Transaction Details Overview This...
Continue Reading
Innovative Design for Racing Safety Recently, a creative inventor conceptualized an advanced support post specifically for horse racing track railings. This inventive solution was born from a desire to lessen the risk of injury to jockeys and horses. The inventor aimed to create a product that enhances safety on race tracks while providing peace of mind for everyone...
Continue Reading
Aurigo Software Partners with Philadelphia for Infrastructure Growth Aurigo Software, known for its expertise in capital planning and construction management, has announced a significant partnership with the City of Philadelphia. This multiyear contract aims to leverage Aurigo's leading product suite, Masterworks, to improve infrastructure program management for the city....
Continue Reading